Humacyte, Inc. (NASDAQ:HUMA) Q4 2022 Earnings Call Transcript

Dale Sander: No Bruce we — I’ll go ahead. Yes.

Heather Prichard: No, Bruce. Nice to talk to you. We have not had that scheduled yet. So that pre-approval inspection will be scheduled by the FDA after they get our filing, our BLA filing. So it will be scheduled by them after we file.

Bruce Jackson: Okay. Great. And then one quick follow-up on the earlier stage programs. Will there be any publications, presentations, et cetera, on the CABG program or the BVP program this year?

Laura Niklason: Yes. So we certainly expect that. We are — we have made submissions to various national, international meetings already on the BVP program, and we expect to continue to present on the CABG program. I’m not really in a position to let you know which meetings we’re presenting at, but these are both active primate level programs. And so we’re going to continue to keep the market appraised.

Bruce Jackson: Okay, great. That’s it from me. Congratulations again on the progress during the quarter.

Operator: I’m showing no further questions in the queue at this time. This concludes Humacyte fourth quarter and year-end 2022 results conference call. Thank you all for participating. You may now disconnect your lines.